For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 14,540 | |||
| General and administrative | 11,772 | |||
| Loss from operations | -26,312 | |||
| Other income, net | 345 | |||
| Net loss | -25,967 | |||
| Dividend attributable to down round feature of warrants | 1,571 | |||
| Net loss attributable to common stockholders | -27,538 | |||
| Basic EPS | -87.27 | |||
| Diluted EPS | -87.27 | |||
| Basic Average Shares | 315,535 | |||
| Diluted Average Shares | 315,535 | |||
Aptevo Therapeutics Inc. (APVO)
Aptevo Therapeutics Inc. (APVO)